Novartis Pharmeceuticals Corporation and the US-Food and Drug Administration or US-FDA informed the dental healthcare experts about the changes to the prescribing information to define the occurrence of Osteonecrosis of the Jaw or ONJ experienced by cancer patients who are undergoing the intravenous bisphosphonate medications. Novartis produces and sells Aredia and Zometa, medicines that help prevent cancer of bone loss and metastases (a condition where cancer cells penetrate the bones). This prescribing information suggests that cancer patients should undergo dental examination before taking any bisphosphonate medication and refrain from having dental treatments while taking Aredia medication.